Short and long term intraocular pressure changes after intravitreal injections of triamcinolone acetonide and bevacizumab in diabetic macular edema

Rawal Medical Journal

Volumn 39, Issue 4, 2014, Pages 443-445

  Ali, Mahmood ^a   Khan, Furqan Ahmad ^a   Zafar, Sarah ^a   Akhtar, Farah ^a  

^a AL SHIFA TRUST EYE HOSPITAL   (Pakistan)

Author keywords

Anti VEGF; Bevacizumab; Diabetic macular edema; Intra ocular pressure; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; CIPROFLOXACIN; OFLOXACIN; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; DIABETIC MACULAR EDEMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84911932511     PISSN: 03035212     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Lee K, Chung H, Park Y, Sohn J. Efficacy of Intravitreal Anti-vascular Endothelial Growth Factor or Steroid Injection in Diabetic Macular Edema According to Fluid Turbidity in Optical Coherence Tomography. Korean J Ophthalmol 2014; 28: 298-305.
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 280516.
3. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-9.
4. Mason JO 3rd, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006; 26: 356-7.
5. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-8.
6. McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981; 91: 7858.
7. Conway MD. The problem of pressure elevation associated with intravitreal triamcinolone. Br J Ophthalmol 2006; 90: 934-5.
8. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative and angiogenic diseases. Prog Ret Eye Res 2005; 5: 587611.
9. Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013; 120: 1835-42.
10. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med 2014; 160: 18-29.
11. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complications 2010; 24: 84-9.
12. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92: 76-80.
13. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 9207.
14. Azad R, Sain S, Sharma YR, Mahajan D. Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study. Oman Jophthalmol 2012; 5: 166-70.
15. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-8.
16. Kemt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007; 85: 119-20.